Search

Your search keyword '"Ouwerkerk J"' showing total 95 results
Start Over Author "Ouwerkerk J" Database OpenAIRE
95 results on '"Ouwerkerk J"'

1. Soumaya Sahla geen tweede kans gunnen is onliberaal en de rechtsstaat onwaardig

Author

Meijer, S., Jacobs, P., and Ouwerkerk, J.

Subjects
Foundational principles & fundamental rights (transition), Grondslagen van het publiekrecht, Principles of Public Law, Dragende beginselen & fundamentele rechten (overgangssituatie)
Abstract

Item does not contain fulltext 15 februari 2022

Published
2022

3. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients

Author

Timmer-Bonte, J.N.H., Ouwerkerk, J., Faber, L.M., Kerkhofs, L.G., Laterveer, L., Oever, D. Ten, Rees, B.P. van, and Linden, P.W. Van Der

Subjects
Other Research Radboud Institute for Health Sciences [Radboudumc 0]
Abstract

Item does not contain fulltext BACKGROUND: Chemotherapy (CT)-induced neutropenia and febrile neutropenia (FN) can lead to changes in the treatment plan, potentially worsening the cancer outcome. This study evaluated the effect of the glycopegylated granulocyte-colony stimulating factor lipegfilgrastim, used as primary (PP) or secondary prophylaxis (SP), on treatment modifications in adult patients receiving cytotoxic CT with or without biological/targeted therapy (BT) for solid and haematological tumours. METHODS: This phase 4, prospective, observational study was conducted in eight centres in the Netherlands, in 2015-2017. Other study objectives were to characterise the population of cancer patients receiving lipegfilgrastim, to evaluate the incidence of CT-induced neutropenic events, and to assess safety. RESULTS: Of 142 patients, 73.94% had breast cancer and 55.63% received CT in the adjuvant setting. Most patients received lipegfilgrastim as PP (74.65%) and were at low (34.51%) or high risk (39.44%) of FN. CT dose delays were recorded for 22.64% and 36.11% of patients receiving lipegfilgrastim for PP and SP, respectively. CT dose reductions were recorded for 2.11% of patients; no CT dose omissions and one BT dose omission occurred. FN and grade III/IV neutropenia were reported for 5.63% and 9.86% of patients, respectively; associated hospitalisations were rare. The most frequently lipegfilgrastimrelated adverse events (AE) were myalgia, bone pain, and back pain. Serious AEs (55) were reported for 30 (21.13%) patients. There were two deaths, unrelated to lipegfilgrastim administration. CONCLUSION: Administration of lipegfilgrastim in routine clinical practice in the Netherlands results in limited CT/BT dose modifications and low incidence of neutropenic events, with no new safety concerns.

Published
2020

9. Assessment of an optimistic bias in social media messages

Author

Suzana Bašić, Spijkers, Benthe S., Ouwerkerk, J. W., Vermeulen, I. E., Guido van Koningsbruggen, Antske Fokkens, and Vermeulen, Ivar

Subjects
SDG 10 - Reduced Inequalities
Abstract

Consistent with psychological theory and research, in the present study we demonstrate that people display a generic optimistic bias by showing more positive sentiment in social media messages about the future rather than the past. In addition, we outline a method for evaluating the validity of the commercial monitoring tool used for the automated sentiment analysis, thereby assessing the usefulness of such a tool in web-based research into human behavior.

Published
2018

10. Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Author

Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., Hermsen, I., Hahner, S., Willenberg, H. S., Tabarin, A., Quinkler, M., De La Fouchardiere, C., Schlumberger, M., Mantero, F., Weismann, D., Beuschlein, F., Gelderblom, H., Wilmink, H., Sender, M., Edgerly, M., Kenn, W., Fojo, T., Muller, H. H., Skogseid, B., Haaf, M., Johanssen, S., Koschker, A. C., Laubner, K., Sbiera, S., Schiemann, J., Wortmann, S., Haase, M., Schott, M., Möhlig, M., Zopf, K., Reisch, N., Betz, M., Reincke, M., Isermann, B., Bornstein, S., Fottner, C., Bose, A., Petersenn, S., Leitolf, H., Klose, S., Wolf, H., Chougnet, C., More, J., Nunes, M. L., Droz, J. P., Nicolli, P., Chabre, O., Clergeot, A., Schillo, F., Penfornis, A., Do Cao, C., Goldwasser, F., Rodien, P., Ferrero, A., Perotti, P., Cicala Mv, Anna P., Della Casa, S., Mannelli, M., Piccini, V., Dercksen, M. W., Romijn, J. A., Ouwerkerk, J., Devries, J. H., Eriksson, B., Janson, E. T., Granberg, D., Oberg, K., Ahlman, H., Garkavij, M., Wall, N., Falkmer, U., Hammer, G., Olney, H. J., Bourdeau, I., Bourque, L., Szpak Ulczok, S., Jarzab, M., Holte, H., Fossa, A., Ploner, F., Mansmann, U., Schmoll, H. J., Simonsson, B., Toscano, Vincenzo, Petersenn, Stephan (Beitragende*r), CCA -Cancer Center Amsterdam, Oncology, Other departments, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, General Internal Medicine, and Endocrinology

Subjects
Adult, Male, adrenal tumor, medicine.medical_specialty, Medizin, Kaplan-Meier Estimate, Gastroenterology, Disease-Free Survival, Streptozocin, Young Adult, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Adrenocortical Carcinoma, Medicine, Adrenocortical carcinoma, Humans, Mitotane, Adverse effect, Etoposide, Aged, Intention-to-treat analysis, business.industry, Medicine (all), Hazard ratio, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Adrenal Cortex Neoplasms, Surgery, Intention to Treat Analysis, Regimen, Doxorubicin, Cisplatin, Female, Quality of Life, business, medicine.drug
Abstract

A b s t r ac t Background Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. Methods We randomly assigned 304 patients with advanced adrenocortical carcinoma to re ceive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. Results For first-line therapy, patients in the EDP–mitotane group had a significantly higher response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, P

Published
2012
Full Text
View/download PDF

11. Woord vooraf

Author

Claessen, J., Jacobs, Pauline, Meijer, S., Ouwerkerk, J, Jacobs, P., Ouwerkerk, J., Sub Strafrecht, Montaigne Centrum voor Rechtspleging en conflictoplossing, and UU LEG LAW Landelijke Onderzoekschool Rechten van de Mens

Published
2014

12. Woord vooraf

Author

Claessen, J., Jacobs, Pauline, Meijer, S., Ouwerkerk, J, Jacobs, P., Ouwerkerk, J., Sub Strafrecht, Montaigne Centrum voor Rechtspleging en conflictoplossing, and UU LEG LAW Landelijke Onderzoekschool Rechten van de Mens

Published
2014

14. Vergelding en verzoening versus wraak en vergeving

Author

Tongeren, P.J.M. van, Ouwerkerk, J., De Wit, Th., Ouwerker, J., Wit, Th. de, Ouwerkerk, J., and De Wit, Th.

Subjects
Center for Contemporary European Philosophy (CCEP)
Abstract

Item does not contain fulltext

Published
2013

16. Imitatie en liking: Een functionele benadering

Author

Stel, M., Baaren, R.B. van, Blascovich, J., McCall, C., Pollmann, M.M.H., Leeuwen, M.L. van, Vonk, R., Holland, R.W., Ouwerkerk, J., Laar, C. van, Ruiter, R., Ham, J.R.C., Holland, R.W., Ouwerkerk, J., Laar, C. van, Ruiter, R., and Ham, J.R.C.

Subjects
Behaviour Change and Well-being
Abstract

Item does not contain fulltext

Published
2006

17. Wanneer onbewuste doelen bewust worden

Author

Bongers, K.C.A., Dijksterhuis, A.J., Spears, R., Holland, R.W., Ouwerkerk, J., Laar, C., Ruiter, R., Ham, R.J.C., Holland, R.W., Ouwerkerk, J., Laar, C., Ruiter, R., and Ham, R.J.C.

Subjects
Behaviour Change and Well-being
Abstract

Item does not contain fulltext

Published
2006

18. Affect en intuïtief beslissen

Author

Vries, M. de, Holland, R.W., Witteman, C.L.M., Ouwerkerk, J., Laar, C. van, Ruiter, R., Ham, J.R.C., Holland, R.W., Ouwerkerk, J., Laar, C. van, Ruiter, R., and Ham, J.R.C.

Subjects
Experimental Psychopathology and Treatment, Behaviour Change and Well-being
Abstract

Item does not contain fulltext

Published
2006

19. Effecten van relatie-ervaringen op hechtingsstijl

Author

Kroesbergen, W., Vonk, R., Holland, R.W., Ouwerkerk, J., Laar, C. van, Ruiter, R., Ham, J.R.C., Holland, R.W., Ouwerkerk, J., Laar, C. van, Ruiter, R., and Ham, J.R.C.

Subjects
Behaviour Change and Well-being
Abstract

Item does not contain fulltext

Published
2006

23. Mensbeelden en strafrecht (foto- en interviewboek)

Author

Claessen, J., Jacobs, Pauline, Meijer, S., Ouwerkerk, J, Sub Strafrecht, Montaigne Centrum voor Rechtspleging en conflictoplossing, and UU LEG LAW Landelijke Onderzoekschool Rechten van de Mens

Published
2014

24. Mensbeelden in het strafrecht

Author

Meijer, S., Ouwerkerk, J., Claessen, J.A.A.C., Jacobs, P., Criminal Law, Network Institute, Communication Choices, Content and Consequences (CCCC), Empirical and Normative Studies, and Kooijmans Institute

Published
2014

25. Mensbeelden en strafrecht (foto- en interviewboek)

Author

Claessen, J., Jacobs, Pauline, Meijer, S., Ouwerkerk, J, Sub Strafrecht, Montaigne Centrum voor Rechtspleging en conflictoplossing, and UU LEG LAW Landelijke Onderzoekschool Rechten van de Mens

Published
2014

26. Pedofielen blijven mensen

Author

Claessen, J.A.A.C., Ouwerkerk, J., de Haas, A., Criminal Law and Criminology, RS: FdR RvdM Strafrecht en Crim., RS: FdR Strafrecht en Criminologie, and RS: FdR Institute MCfHR

Published
2013

37. Inleiding

Author

Claessen, J.A.A.C., Ouwerkerk, J., de Wit, Th., Jacobs, P., Meijer, S., Criminal Law and Criminology, RS: FdR RvdM Strafrecht en Crim., RS: FdR Strafrecht en Criminologie, and RS: FdR Institute MCfHR

Published
2013

50. N7-methylguanine and O-6-methylguanine levels in DNA of white blood cells from cancer patients treated with dacarbazine

Author

Delft, J. H. M., Luiten-Schuite, A., Souliotis, V. L., Soterios Kyrtopoulos, Ouwerkerk, J., Keizer, H. J., Baan, R. A., and Instituut CIVO-Toxicologie en Voeding TNO

Subjects
Dacarbazine, N7-methylguanine, N-nitrosamine, O6-methylguanine, Nutrition
Abstract

Methyl-DNA adducts are induced by a number of lifestyle, environmental and occupational carcinogens, however knowledge about their kinetics is scarce. Here, N7-methylguanine (N7-MeGua) and O6-methylguanine (O6-MeGua) levels were determined in the DNA of white blood cells from eight cancer patients treated iv with the antitumour drug dacarbazine (DTIC). Five of the patients were treated with the drug as a single agent (a single dose of 800 mg m-2) and three on three successive days with dacarbazine (225 mg m-2 day-1) in combination with other drugs. The data indicate that maximum adduct levels are reached at 4-8 h after treatment and that the amount of N7-MeGua is at least 20-fold higher than that of O6-MeGua. The half-life of N7-MeGua is 40-96 h and that of O6-MeGua 25-27 h. Following treatment on three consecutive days, an accumulation of N7-MeGua was observed but not of O6-MeGua. The data show substantial interindividual differences in adduct levels but not in the ratio of N7/O6-MeGua. This may reflect differences in the metabolism of dacarbazine or in repair capacities. © 1996 Taylor & Francis Ltd.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results